Oncotelic Therapeutics, Inc. Files 2023 Annual Report (10-K)

TL;DR

<b>Oncotelic Therapeutics, Inc. has filed its 2023 annual report on Form 10-K, detailing its operations and financial status for the fiscal year ending December 31, 2023.</b>

AI Summary

Oncotelic Therapeutics, Inc. (OTLC) filed a Annual Report (10-K) with the SEC on April 12, 2024. Oncotelic Therapeutics, Inc. filed its 2023 annual report on Form 10-K on April 12, 2024. The company was formerly known as Mateon Therapeutics Inc. and Oxigene Inc. The filing covers the fiscal year ending December 31, 2023. The company's business address is 29397 Agoura Rd., #107, Agoura Hills, CA 91301. The Standard Industrial Classification code for the company is Pharmaceutical Preparations [2834].

Why It Matters

For investors and stakeholders tracking Oncotelic Therapeutics, Inc., this filing contains several important signals. This 10-K filing provides a comprehensive overview of Oncotelic's financial performance, business operations, and risk factors for the fiscal year 2023, which is crucial for investors to assess the company's current standing and future prospects. The filing includes historical company information, such as previous names (Mateon Therapeutics Inc., Oxigene Inc.), which is important for understanding the company's evolution and any potential legacy issues or strategic shifts.

Risk Assessment

Risk Level: medium — Oncotelic Therapeutics, Inc. shows moderate risk based on this filing. The company operates in the pharmaceutical preparations industry, which is subject to significant regulatory oversight, lengthy development cycles, and high research and development costs, posing inherent risks to financial performance and market success.

Analyst Insight

Investors should review the detailed financial statements and risk factors in the 10-K to understand Oncotelic's financial health and the challenges it faces in the pharmaceutical sector.

Key Numbers

• 2023-12-31 — Fiscal Year End (Conformed period of report)
• 2024-04-12 — Filing Date (As of date)
• 2834 — SIC Code (Standard Industrial Classification)
• 000-21990 — SEC File Number (SEC file number)

Key Players & Entities

• Oncotelic Therapeutics, Inc. (company) — Filer name
• OTLC (company) — Ticker symbol
• 2023 (date) — Fiscal year end
• 2024-04-12 (date) — Filing date
• Mateon Therapeutics Inc. (company) — Former company name
• Oxigene Inc. (company) — Former company name
• 29397 AGOURA RD. #107 (address) — Business address
• AGUORA HILLS, CA 91301 (address) — Business address

FAQ

Risk Factors

• Regulatory Risks [high — regulatory]: The pharmaceutical industry is heavily regulated, and changes in regulations or failure to comply can adversely affect the company's business, financial condition, and results of operations.
• Financing Risks [high — financial]: The company may require additional financing to fund its operations and development activities, and there is no assurance that such financing will be available on favorable terms or at all.
• Research and Development Risks [high — operational]: The development of pharmaceutical products is a lengthy, expensive, and uncertain process, and there is no guarantee that any of the company's product candidates will successfully complete clinical trials and receive regulatory approval.

Key Dates

• 2023-12-31: Fiscal Year End — Marks the end of the reporting period for the 10-K.

Key Financial Figures

• $0.01 — Exchange Act: Common stock, par value $0.01 per share Indicate by check mark if t

Filing Documents

• form10-k.htm (10-K) — 2971KB
• ex23-1.htm (EX-23.1) — 4KB
• ex31-1.htm (EX-31.1) — 20KB
• ex31-2.htm (EX-31.2) — 20KB
• ex32-1.htm (EX-32.1) — 7KB
• ex32-2.htm (EX-32.2) — 6KB
• 0001493152-24-014475.txt (&nbsp;) — 10908KB
• otlc-20231231.xsd (EX-101.SCH) — 73KB
• otlc-20231231_cal.xml (EX-101.CAL) — 59KB
• otlc-20231231_def.xml (EX-101.DEF) — 370KB
• otlc-20231231_lab.xml (EX-101.LAB) — 506KB
• otlc-20231231_pre.xml (EX-101.PRE) — 447KB
• form10-k_htm.xml (XML) — 1654KB

BUSINESS

BUSINESS 1 REGULATORY MATTERS 13 PATENTS AND PROPRIETARY RIGHTS 18 COMPETITION 19 EMPLOYEES 19 ITEM 1A. RISK FACTORS 20 ITEM 1B. UNRESOLVED STAFF COMMENTS 34 ITEM 2.

PROPERTIES

PROPERTIES 34 ITEM 3. LEGAL PROCEEDINGS 35 ITEM 4. MINE SAFETY DISCLOSURES 35 PART II ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES 35 ITEM 6. RESERVED 35 ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 35 RESULTS OF OPERATIONS 46 LIQUIDITY AND CAPITAL RESOURCES 48 ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 50 ITEM 8. FINANCIAL 50 ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE 50 ITEM 9A. CONTROLS AND PROCEDURES 51 ITEM 9B. OTHER INFORMATION 52 PART III ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE 53 ITEM 11. EXECUTIVE COMPENSATION 57 ITEM 12. SECURITY 64 ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE 66 ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES 68 PART IV ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES 69 i FORWARD-LOOKING This 2023 Annual Report on Form 10-K (this " Annual Report " or " Report ") contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934 (the " Exchange Act ") that involve substantial risks and uncertainties. We generally identify forward-looking statements by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "could," "would," "intend," "target," "aim," "project," "believe," "estimate," "predict," "potential," "seek," "indicate," or "continue" or the negative of these terms or other similar words, although not all forward-looking statements contain these words. Forward-looking statements include, but are not limited to, statements regarding our or our management's expectations,

View Full Filing

View this 10-K filing on SEC EDGAR